BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26342406)

  • 1. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Gorodnova TV; Sokolenko AP; Ivantsov AO; Iyevleva AG; Suspitsin EN; Aleksakhina SN; Yanus GA; Togo AV; Maximov SY; Imyanitov EN
    Cancer Lett; 2015 Dec; 369(2):363-7. PubMed ID: 26342406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
    Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    Sokolenko AP; Bizin IV; Preobrazhenskaya EV; Gorodnova TV; Ivantsov AO; Iyevleva AG; Savonevich EL; Kotiv KB; Kuligina ES; Imyanitov EN
    Int J Cancer; 2020 Apr; 146(7):1879-1888. PubMed ID: 31693165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
    Gorodnova TV; Maksimov SIa; Guseń≠nov KD; Imianitov EN
    Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
    Sokolenko A; Preobrazhenskaya E; Marchetti C; Piermattei A; Zagrebin F; Kuligina E; Gorodnova T; Pavone M; Ivantsov A; Bizin I; Scambia G; Berlev I; Fagotti A; Imyanitov E
    Pathobiology; 2024; 91(2):108-113. PubMed ID: 37579727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
    King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
    Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
    Safra T; Rogowski O; Muggia FM
    Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.
    Rodríguez AO; Llacuachaqui M; Pardo GG; Royer R; Larson G; Weitzel JN; Narod SA
    Gynecol Oncol; 2012 Feb; 124(2):236-43. PubMed ID: 22044689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
    Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
    Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
    Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
    Ginolhac SM; Gad S; Corbex M; Bressac-De-Paillerets B; Chompret A; Bignon YJ; Peyrat JP; Fournier J; Lasset C; Giraud S; Muller D; Fricker JP; Hardouin A; Berthet P; Maugard C; Nogues C; Lidereau R; Longy M; Olschwang S; Toulas C; Guimbaud R; Yannoukakos D; Szabo C; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Goldgar D; Stoppa-Lyonnet D; Lenoir GM; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):90-5. PubMed ID: 12582017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.